Of note, loss or downregulation of E-cadherin together with de novo expression or upregulation of N-cadherin has been implicated in the process of EMT in different types of carcinoma and has been correlated to an unfavorable prognosis (the so-called “cadherin switch”) [49,50]. The gene discussed is CDH2; the disease is carcinoma.